All In Biotech

Drug Trial Radar · NCT05948813

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

A Phase II Study of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain Metastases

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Aug 17, 2023

Primary completion

Dec 15, 2025

Study completion Mar 30, 2030

Sponsor

Lead sponsor
TYK Medicines, IncIndustry
Sponsor type
Industry
First posted
Jul 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the efficacy and safety of TY-9591 in first-line treatment of patients with EGFR-sensitive mutation-positive non-small cell lung cancer with brain metastases compared to Osimertinib.

Conditions

  • NSCLC
  • EGFR Activating Mutation
  • Brain Metastases

Interventions

  • TY-9591Drug

    The dose of TY-9591 tablet is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.

  • OsimertinibDrug

    The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intracranial Overall Response Rate (iORR)Time frame: 36 months
  2. Intracranial Median Progression Free Survival (iPFS)Time frame: 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.